Enzene Biosciences has announced the formation of a new drug discovery branch. This broadens the CDMO's service offerings to the biotech industry and complements its EnzeneXTM-equipped biologics manufacturing location in the United States, which...
Piramal Pharma has recorded robust financial growth during the final quarter ended March 2024 and its united net benefit has taken a quantum bounce of 102% to Rs. 101 crore from Rs. 50 crore in the relating time of the year before. Its incomes...
Merck, a pharmaceutical firm, and Eyebiotech Limited (EyeBio), ophthalmology-centered biotechnology organization, reported that the organizations have gone into a conclusive arrangement under which Merck, through a subsidiary, will acquire...
A clinical trial agreement has been reached between Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company, and the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health...
Asahi Kasei Corp. declares that Asahi Kasei will acquire the shares of the drug organization Calliditas to make Calliditas an entirely owned subsidiary of Asahi Kasei through a deliberate delicate proposal for Calliditas. The Tender Offer will...
The U.S. Food and Drug Administration sanctioned Amgen's Bkemv, the first biosimilar to AstraZeneca's intriguing blood problem treatment Soliris. Amgen's medication will be advertised under the name Bkemv. Biosimilars are close duplicates of...
AstraZeneca Pharma India Ltd's net profit for the quarter ended March 31, 2024 has doubled to Rs. 39.48 crore, up from Rs. 17.27 crore in the same time last fiscal year. Total income increased 34% to Rs. 391.86 crore during the quarter, compared...
In a huge clinical achievement, Chinese researchers have effectively cured a patient's diabetes utilizing a groundbreaking cell therapy. This spearheading treatment was created by a group from Shanghai Changzheng Emergency clinic, the Centre for...
Oncocross, a pharmaceutical firm, declared on May 22nd that it has consented to a joint exploration arrangement with JW Pharmaceutical to foster new medications in view of the AI platform. Under this agreement, the two organizations will join...
Shanghai Henlius Biotech, Inc., a global biopharmaceutical firm, and Organon reported that the European Medicines Agency (EMA) has approved the marketing authorization applications (MAAs) for HLX14, an experimental Prolia and Xgeva (denosumab)...
, CDSCO.jpg)
